Examination of the substrate specificity of heparin and heparan sulfate lyases.
about
Structural differences and the presence of unsubstituted amino groups in heparan sulphates from different tissues and speciesStructural basis of heparan sulfate-specific degradation by heparinase IIIEndocytotic Routes of Cobra Cardiotoxins Depend on Spatial Distribution of Positively Charged and Hydrophobic Domains to Target Distinct Types of Sulfated Glycoconjugates on Cell SurfaceThe degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanasesReceptors for fibroblast growth factorsHeparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomasPanels of chemically-modified heparin polysaccharides and natural heparan sulfate saccharides both exhibit differences in binding to Slit and Robo, as well as variation between protein binding and cellular activityCapillary electrophoresis for the analysis of glycosaminoglycans and glycosaminoglycan-derived oligosaccharides.Heparan sulfate, heparin, and heparinase activity detection on polyacrylamide gel electrophoresis using the fluorochrome tris(2,2'-bipyridine) ruthenium (II).Mass spectrometric evidence for the enzymatic mechanism of the depolymerization of heparin-like glycosaminoglycans by heparinase II.Sequencing of 3-O sulfate containing heparin decasaccharides with a partial antithrombin III binding site.Effects of sulfate position on heparin octasaccharide binding to CCL2 examined by tandem mass spectrometry.Identification and characterization of a novel cell-penetrating peptideScreening for anticoagulant heparan sulfate octasaccharides and fine structure characterization using tandem mass spectrometryHeparin Promotes Cardiac Differentiation of Human Pluripotent Stem Cells in Chemically Defined Albumin-Free Medium, Enabling Consistent Manufacture of CardiomyocytesCharacterizing molecular diffusion in the lens capsuleNot all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.Analysis of glycosaminoglycan-derived disaccharides by capillary electrophoresis using laser-induced fluorescence detectionNMR methods to monitor the enzymatic depolymerization of heparin.Capillary electrophoresis for the analysis of glycosaminoglycan-derived disaccharides.Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection.Comparative assessment of the effects of gender-specific heparan sulfates on mesenchymal stem cellsCrosslinking decreases the hemocompatibility of decellularized, porcine small intestinal submucosa.Heparinase inhibits neovascularization.Cloning and expression of heparinase I gene from Flavobacterium heparinum.The Responses of Hyperglycemic Dividing Mesangial Cells to Heparin Are Mediated by the Non-reducing Terminal Trisaccharide.Glycan antagonists and inhibitors: a fount for drug discovery.Liquid chromatography-mass spectrometry to study chondroitin lyase action pattern.Fluorescent-tagged heparan sulfate precursor oligosaccharides to probe the enzymatic action of heparitinase I.Chlamydia-dependent biosynthesis of a heparan sulphate-like compound in eukaryotic cells.Microbial heparin/heparan sulphate lyases: potential and applications.Screening enoxaparin tetrasaccharide SEC fractions for 3-O-sulfo-N-sulfoglucosamine residues using [(1)H,(15)N] HSQC NMR.Profiling glycol-split heparins by high-performance liquid chromatography/mass spectrometry analysis of their heparinase-generated oligosaccharides.Fibrillin-1 interactions with heparin. Implications for microfibril and elastic fiber assembly.Heparin-like structures on respiratory syncytial virus are involved in its infectivity in vitro.Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor.Syndecan-1 and -4 synthesized simultaneously by mouse mammary gland epithelial cells bear heparan sulfate chains that are apparently structurally indistinguishable.Heparinase I from Flavobacterium heparinum. Mapping and characterization of the heparin binding domain.Basic fibroblast growth factor does not prevent heparan sulphate proteoglycan catabolism in intact cells, but it alters the distribution of the glycosaminoglycan degradation products.Sequence analysis of heparan sulphate indicates defined location of N-sulphated glucosamine and iduronate 2-sulphate residues proximal to the protein-linkage region.
P2860
Q24530061-7D5E4419-3E7A-4BA5-B898-0E5CF56618B8Q27673616-3EBE1762-6B45-41B9-B041-71FD5677A394Q27684078-8773C632-43D0-4A34-9937-351D7F90882AQ28278296-67A83A4B-CBB8-4277-BD8F-D26760C28DEAQ28285082-1743B9FB-1112-448E-BBA8-332BA4980953Q28344801-A3A60358-5BC0-4F98-B6D9-CC09244DDF37Q28822558-70619E94-1FF8-48A7-87DF-857AC7FE2049Q30816655-183E0785-EB3F-4C0C-A950-DEF54CC9A46EQ31986916-AF33A812-09CE-4C93-8A9A-AB70DEF93314Q32000531-5C15E06D-EF2D-47F5-A3DE-C7A13FCAA69FQ33181061-E2B9844E-76CF-40D6-B0C0-FED9961A829BQ33245170-44EEC172-F2D3-4F20-83D8-9B95F8651E24Q33393157-A981F53D-FE3C-4636-8E72-B1A063EBD8B9Q33546538-F75C209B-3A1C-45F4-9A1F-C243C1A83519Q33722559-0B6F7301-1AA0-4761-A3D2-92F9D6F2122EQ33770847-8A193ED2-C909-473B-98A8-152136795D62Q34114308-F13A7091-D1F7-4348-A484-6CF0A3F18BFAQ34275145-F78A4E5C-E539-4CBB-9249-9651A43B4249Q34463103-F1F4114B-8CD5-4698-A5A4-46120C12EE91Q34578102-403E3C5B-8572-4D0F-B752-3F23844EEBFBQ34825946-24BE523F-B055-4970-AA3B-1B598C40DF05Q34978967-402700D6-C6AC-415C-B1F4-38F242B2DE75Q35019631-AE09B93E-B638-4037-921A-19A43E7C55B4Q35056165-D3BA3ACD-208D-442B-A96F-1DAE5AA79D39Q36257092-3992F5E9-A912-433F-B382-CF5FF3F543C1Q36323528-C841DA52-B118-4F52-A46A-89FD39AAC295Q37027396-28711ACE-2A29-4D11-9F55-003D6BBCEBE0Q37085832-799AB5AB-6F82-44E7-B9B1-02AA280F1816Q37469129-24748A9E-F7F2-4667-AA26-CA1CBDD420A0Q37874931-80F48B35-5751-4171-BCD5-8D5AEA1B59BDQ37990767-696734F7-78A5-4A72-9582-BFC6C619B997Q38294362-4BB7C49C-7230-4726-8361-3C6B6531B554Q38319635-76390B30-8EA7-4653-B8F7-99CEE3FB5FEEQ38324440-67E5A2A2-FBA9-46D0-8C59-E68C601EC83DQ38334591-196D3322-9459-4069-AD81-F05B072CFFD5Q38349679-DCDAC794-E908-4279-8BF4-37D837A1CFACQ38357933-27FA0D36-DF60-4358-95FE-5B23D28AAF87Q38361800-4455F203-6FB2-46A3-AD73-18F08460A4ECQ38461758-6E57DD19-AD29-4285-B98C-25B47909F3C6Q41777711-2A3F3F85-1EC1-471F-AC12-A2BDBB1F5546
P2860
Examination of the substrate specificity of heparin and heparan sulfate lyases.
description
1990 nî lūn-bûn
@nan
1990 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի մարտին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Examination of the substrate specificity of heparin and heparan sulfate lyases.
@ast
Examination of the substrate specificity of heparin and heparan sulfate lyases.
@en
Examination of the substrate specificity of heparin and heparan sulfate lyases.
@nl
type
label
Examination of the substrate specificity of heparin and heparan sulfate lyases.
@ast
Examination of the substrate specificity of heparin and heparan sulfate lyases.
@en
Examination of the substrate specificity of heparin and heparan sulfate lyases.
@nl
prefLabel
Examination of the substrate specificity of heparin and heparan sulfate lyases.
@ast
Examination of the substrate specificity of heparin and heparan sulfate lyases.
@en
Examination of the substrate specificity of heparin and heparan sulfate lyases.
@nl
P2093
P356
P1433
P1476
Examination of the substrate specificity of heparin and heparan sulfate lyases.
@en
P2093
Gallagher JT
Loganathan D
Turnbull JE
P304
P356
10.1021/BI00462A026
P407
P577
1990-03-01T00:00:00Z